Laurus Company Profile
What is the competitive landscape for LAURUS
LAURUS has eighteen approved drugs.
There are eight tentative approvals on LAURUS drugs.
Summary for Laurus
| US Patents: | 0 |
| Tradenames: | 15 |
| Ingredients: | 15 |
| NDAs: | 18 |
| Patent Litigation for Laurus: | See patent lawsuits for Laurus |
Drugs and US Patents for Laurus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus | PIRFENIDONE | pirfenidone | TABLET;ORAL | 212722-001 | Jul 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | HYDROXYCHLOROQUINE SULFATE | hydroxychloroquine sulfate | TABLET;ORAL | 210959-001 | Jan 15, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | PIRFENIDONE | pirfenidone | CAPSULE;ORAL | 212724-001 | Jul 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 212786-001 | May 14, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | RILPIVIRINE HYDROCHLORIDE | rilpivirine hydrochloride | TABLET;ORAL | 219788-001 | Jul 10, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

